US 7,740,859 B2 · Polypeptides for the diagnosis and therapy of Leishamaniasis

Abstract

The present invention provides compounds and methods for the detection of anti-leishmanial antibodies in individuals suspected of infection with the protozoan parasite of the genus Leishmania, where the infectious agent is an Indian strain and similar or closely related to Indian Leishmania strains. The compounds provided include polypeptides as shown in SEQ ID NO: 5 or SEQ ID NO: 6 which are useful for the detection of anti-leishmanial antibodies in individuals where the immune responses are elicited against Leishmania species of Indian strains and similar or closely related to Indian Leishmania strains, the compounds are also useful as a vaccine and therapeutic agent to prevent and treat leishmaniasis. The present invention further provides a diagnostic kit consisting of antibody raised against polypeptides as shown in SEQ ID NO: 5 or SEQ ID NO: 6 for detecting leishmanial antigens.

Claims23

Dependent claims

An isolated polypeptide, comprising the amino acid sequence as recited in SEQ ID NO:

5 or SEQ ID NO:
6, wherein said polypeptide has an immunogenic region of a Leishmania antigen.

Dependencies are inferred from the claim text.

Facts

Application

10/584,451Filed 26 Dec 2003

Published

US 2008/0031878 A17 Feb 2008

Granted

22 Jun 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07K 14/44
From animals; from humans: from protozoa
A61P 33/02
Antiparasitic agents: antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
G01N 33/56905
For microorganisms, e.g. protozoa, bacteria, viruses: protozoa
G01N 2469/20
Immunoassays for the detection of microorganisms: detection of antibodies in sample from host which are directed against antigens from microorganisms

Polypeptides for the diagnosis and therapy of Leishamaniasis

Life of this patent

Polypeptides for the diagnosis and therapy of Leishamaniasis

Life of this patent

Abstract

Claims23